TBC ISBT Product Codes Rev Revised ISBT US Product Name. E WHOLE BLOOD CPD/500ml/refg Irradiated ResLeu:<5log6 7/21/2008
|
|
|
- Ilene Manning
- 5 years ago
- Views:
Transcription
1 E WHOLE BLOOD CPD/500mL/refg E WHOLE BLOOD CPD/500mL/refg Irradiated E WHOLE BLOOD CPD/500ml/refg Irradiated ResLeu:<5log6 7/21/2008 E WHOLE BLOOD CPD/500mL/refg ResLeu:<5log6 E WHOLE BLOOD CPD/XX/refg LowVol:anticoag not adj 7/11/2007 E WHOLE BLOOD CPDA-1/500mL/refg E WHOLE BLOOD CPDA-1/500mL/refg Irradiated E WHOLE BLOOD CPDA-1/500mL/refg Irradiated ResLeu:<5log6 E WHOLE BLOOD CPDA-1/500mL/refg ResLeu:<5log6 E WHOLE BLOOD CPDA-1/XX/refg LowVol:anticoag not adj 7/11/2007 E WHOLE BLOOD CP2D/450ml/refg 7/11/2007 E RED BLOOD CELLS CPD/500ml/refg E RED BLOOD CELLS CPD/500mL/refg For mnf:noninjectable 7/11/2007 E RED BLOOD CELLS CPD/500mL/refg Irradiated 7/11/2007 E RED BLOOD CELLS CPD/500mL/refg Irradiated ResLeu:<5log6 E RED BLOOD CELLS CPD/500mL/refg ResLeu:<5log6 E RED BLOOD CELLS CPDA-1/450mL/refg 8/19/2008 E RED BLOOD CELLS CPDA-1/450mL/refg Irradiated 8/19/2008 E RED BLOOD CELLS CPDA-1/450mL/refg ResLeu:<5log6 7/28/2010 E RED BLOOD CELLS CPDA-1/500ml/refg E RED BLOOD CELLS CPDA-1/500mL/refg For mnf:noninjectable Not for Txn E RED BLOOD CELLS CPDA-1/500mL/refg Irradiated E RED BLOOD CELLS CPDA-1/500ml/refg Irradiated ResLeu:<5log6 E RED BLOOD CELLS CPDA-1/500mL/refg ResLeu:<5log6 E RED BLOOD CELLS CPDA-1/XX/refg LowVol:anticoag not adj E RED BLOOD CELLS CPD>AS1/450mL/refg For mnf:noninjectable Not for Txn E RED BLOOD CELLS CPD>AS1/500mL/refg E0316 A0 RED BLOOD CELLS CPD>AS1/500mL/refg 7/28/2010 E0316 B0 RED BLOOD CELLS CPD>AS1/500mL/refg 7/28/2010 E0317 RED BLOOD CELLS CPD>AS1/500mL/refg/For mnf:injectable Page 1 of 14
2 E Red Blood Cells CPD > AS1/500mL/refg/For mnf:noninectable Not for Txn E RED BLOOD CELLS CPD>AS1/500mL/refg Irradiated E RED BLOOD CELLS CPD>AS1/500mL/refg Irradiated ResLeu:<5log6 E RED BLOOD CELLS CPD>AS1/500mL/refg ResLeu:<5log6 E RED BLOOD CELLS CP2D>AS3/450mL/refg For mnf:noninjectable Not for Txn E RED BLOOD CELLS CP2D>AS3/500mL/refg E RED BLOOD CELLS CP2D>AS3/500mL/refg For mnf:noninjectable Not for Txn E RED BLOOD CELLS CP2D>AS3/500mL/refg Irradiated E RED BLOOD CELLS CP2D>AS3/500mL/refg Irradiated ResLeu:<5log6 E RED BLOOD CELLS CP2D>AS3/500mL/refg ResLeu:<5log6 E RED BLOOD CELLS CPD>AS5/450mL/refg For mnf:noninjectable Not for Txn E RED BLOOD CELLS CPD>AS5/450mL/refg 8/19/2008 E RED BLOOD CELLS CPD>AS5/450mL/refg Irradiated 8/19/2008 E RED BLOOD CELLS CPD>AS5/500mL/refg E RED BLOOD CELLS CPD>AS5/500mL/refg For mnf:noninjectable Not for Txn E RED BLOOD CELLS CPD>AS5/500mL/refg Irradiated E RED BLOOD CELLS CPD>AS5/500ml/refg Irradiated ResLeu:<5log6 E RED BLOOD CELLS CPD>AS5/500mL/refg ResLeu:<5log6 E RED BLOOD CELLS CPD>AS1/XX/refg LowVol:anticoag not adj E Frozen RED BLOOD CELLS None/XX/<-65C Open 9/9/2008 E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg Irradiated E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg Irradiated ResLeu:<5log6 E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg Irradiated ResLeu:<5log6 1st E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg Irradiated ResLeu:<5log6 2nd E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg Irradiated 1st E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg Irradiated 2nd E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg ResLeu:<5log6 E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg ResLeu:<5log6 1st E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg ResLeu:<5log6 2nd Page 2 of 14
3 E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg 1st E Apheresis RED BLOOD CELLS CP2D>AS3/XX/refg 2nd E FRESH FROZEN PLASMA CPD/XX/<=-18C E0701 A0 FRESH FROZEN PLASMA CPD/XX/<=-18C E0701 B0 FRESH FROZEN PLASMA CPD/XX/<=-18C E0701 C0 FRESH FROZEN PLASMA CPD/XX/<=-18C E0701 D0 FRESH FROZEN PLASMA CPD/XX/<=-18C E FRESH FROZEN PLASMA CPD/XX/<=-18C Not for txn or mnf Not for Txn E FRESH FROZEN PLASMA CPD/XX/<=-18C Quar >6m /retested 7/11/2007 E FRESH FROZEN PLASMA CPDA-1/XX/<=-18C E0707 A0 FRESH FROZEN PLASMA CPDA-1/XX/<=-18C E0707 B0 FRESH FROZEN PLASMA CPDA-1/XX/<=-18C E0707 C0 FRESH FROZEN PLASMA CPDA-1/XX/<=-18C E0707 D0 FRESH FROZEN PLASMA CPDA-1/XX/<=-18C E FRESH FROZEN PLASMA CP2D/XX/<=-18C 1/16/2009 E Thawed FRESH FROZEN PLASMA CPD/XX/refg 7/21/2008 E0773 A0 Thawed FRESH FROZEN PLASMA CPD/XX/refg 7/21/2008 E0773 B0 Thawed FRESH FROZEN PLASMA CPD/XX/refg 7/21/2008 E0773 C0 Thawed FRESH FROZEN PLASMA CPD/XX/refg 7/21/2008 E0773 D0 Thawed FRESH FROZEN PLASMA CPD/XX/refg 7/21/2008 E Thawed FRESH FROZEN PLASMA CPDA-1/XX/refg 6/1/2011 E Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C E Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C E0869 A0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C E0869 B0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C E0869 C0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C E0869 D0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C E0869 E0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C 7/28/2010 E Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C <200 ml E Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C >=200 ml <400mL Page 3 of 14
4 E Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C >=400mL <600mL E Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C >=600mL E0904 A0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C >=600mL 7/21/2008 E0904 B0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C >=600mL 7/21/2008 E0904 C0 Apheresis FRESH FROZEN PLASMA ACD-A/XX/<=-18C >=600mL 7/21/2008 E Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C >=400mL<600mL 10/10/2016 E Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C >=600mL 10/10/2016 E Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C Quar >6m /retested 7/11/2007 E Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX/refg >=200mL <400mL 7/21/2008 E Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX/refg >=400mL <600mL 7/21/2008 E Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX/refg >=600mL 7/21/2008 E1320 A0 Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX/refg >=600mL 7/21/2008 E1320 B0 Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX/refg >=600mL 7/21/2008 E1320 C0 Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX/refg >=600mL 7/21/2008 E Apheresis PLASMA ACD-A/XX/<=-18C Frozen <=24h 10/10/2016 E Liquid PLASMA CPD/XX/refg E Liquid PLASMA CPDA-1/XX/refg E Liquid PLASMA CP2D/XX/refg E Liquid PLASMA CPD/XX/<37C For mnf:noninjectable Not for Txn E Liquid PLASMA CPDA-1/XX/<37C For mnf:noninjectable Not for Txn E RECOVERED 'PLASMA CPD/XX/<=-18C For mnf:injectable Frozen <=24h Not for Txn E RECOVERED PLASMA CPD/XX/<=-18C For mnf:noninjectable Not for Txn E PLASMA CPD/XX/<=-18C Cryo reduced E PLASMA CPD/XX/<=-18C Frozen <=24h 5/13/2008 E RECOVERED 'PLASMA CPDA-1/XX/<=-18C For mnf:injectable Frozen <=24h Not for Txn E RECOVERED PLASMA CPDA-1/XX/<=-18C For mnf:noninjectable. Not for Txn E PLASMA CPDA-1/XX/<=-18C Cryo reduced E PLASMA CPDA-1/XX/<=-18C Frozen <=24h 7/21/2008 E Thawed PLASMA CPD/XX/refg 7/6/2011 E Thawed PLASMA CPD/XX/refg Cryo reduced 7/28/2010 Page 4 of 14
5 E Thawed PLASMA CP2D/XX/refg Cryo reduced 7/28/2010 E PLATELETS CPD/500ml/20-24C E PLATELETS CPD/500mL/20-24C Irradiated E PLATELETS CPD/500/20-24C Irradiated ResLeu:<8.3log5 7/11/2007 E Platelets CPD/500mL/20-24C ResLeu:<8.3log5 E PLATELETS CPDA-1/450mL/20-24C Irradiated 12/1/2011 E PLATELETS CPDA-1/500mL/20-24C E PLATELETS CPDA-1/500mL/20-24C Irradiated E Platelets CPDA-1/500mL/20-24C ResLeu:<8.3log5 E Apheresis PLATELETS ACDA-A/XX/<37C For mnf:noninjectable Not for Txn E Apheresis PLATELETS ACD-A/XX/20-24C E Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 11/12/2007 E2984 A0 Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 9/9/2008 E2984 B0 Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 9/9/2008 E E2986 E2986 A0 B0 E E2987 E2987 A0 B0 E Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 1st Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 1st Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 1st Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 2nd Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 2nd Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 2nd Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 3rd 11/12/2007 9/9/2008 9/9/ /12/2007 9/9/2008 9/9/ /12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated Plasma reduced 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated Plasma reduced 1st 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated Plasma reduced 2nd 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open Irradiated Plasma reduced 3rd 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open ResLeu:<5log6 Plasma reduced 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open ResLeu:<5log6 Plasma reduced 1st 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open ResLeu:<5log6 Plasma reduced 2nd 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open ResLeu:<5log6 Plasma reduced 3rd 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open ResLeu:<5log6 3rd 7/11/2007 Page 5 of 14
6 E Apheresis PLATELETS ACD-A/XX/20-24C Open Plasma reduced 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open Plasma reduced 1st 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open Plasma reduced 2nd 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Open Plasma reduced 3rd 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5log6 E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5log6 1st E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5log6 2nd E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5log6 3rd 7/11/2007 E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated 1st E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated 2nd E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5log6 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5log6 1st E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5log6 2nd E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5log6 3rd 11/12/2007 E Apheresis PLATELETS ACD-A/XX/20-24C 1st E ApheresisPLATELETS ACD-A/XX/20-24C 2nd E Apheresis PLATELETS ACD-A/XX/20-24C 3rd 10/10/2016 E Apheresis PLATELETS ACD-B/XX/20-24C E Apheresis PLATELETS ACD-B/XX/20-24C Irradiated E Apheresis PLATELETS ACD-B/XX/20-24C Irradiated ResLeu:<5log6 E Apheresis PLATELETS ACD-B/XX/20-24C Irradiated ResLeu:<5log6 1st E Apheresis PLATELETS ACD-B/XX/20-24C Irradiated ResLeu:<5log6 2nd E Apheresis PLATELETS ACD-B/XX/20-24C Irradiated 1st E Apheresis PLATELETS ACD-B/XX/20-24C Irradiated 2nd E Apheresis PLATELETS ACD-B/XX/20-24C ResLeu:<5log6 E Apheresis PLATELETS ACD-B/XX/20-24C ResLeu:<5log6 1st E Apheresis PLATELETS ACD-B/XX/20-24C ResLeu:<5log6 2nd E Apheresis PLATELETS ACD-B/XX/20-24C 1st E Apheresis PLATELETS ACD-B/XX/20-24C 2nd Page 6 of 14
7 E Washed Apheresis PLATELETS None/XX/20-24C Open 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open Irradiated 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open Irradiated ResLeu:<5log6 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open Irradiated ResLeu:<5log6 1st 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open Irradiated ResLeu:<5log6 2nd 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open Irradiated 1st 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open Irradiated 2nd 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open ResLeu:<5log6 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open ResLeu:<5log6 1st 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open ResLeu:<5log6 2nd 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open 1st 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open 2nd 6/1/2011 E CRYOPRECIPITATE None/500mL/<=-18C 12/20/2011 E Apheresis GRANULOCYTES NaCitrate-HES/XX/rt Open 1/18/2008 E Apheresis GRANULOCYES Na Citrate-HES/XX/rt Open Irradiated 1/18/2008 E LEUKOCYTES CPD/500mL/refg 4/30/2008 E LEUKOCYTES CPD/500mL/rt Not for tx or mnf Not for Txn E Washed Apheresis RED BLOOD CELLS None/XX/refg Open 7/28/2010 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated 7/28/2010 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 7/28/2010 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 11/12/2007 E WHOLE BLOOD CPD/XX/refg LowVol:anticoag adj 7/21/2008 E WHOLE BLOOD CPDA-1/XX/refg LowVol:anticoag adj 7/21/2008 E RED BLOOD CELLS CPDA-1/XX/refg LowVol:anticoag adj E RED BLOOD CELLS CPD>AS1/XX/refg LowVol:anticoag adj E RECOVERED PLASMA CPD/XX/<=-18C For mnf:injectable Frozen <=120h E Deglycerolized RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 E Deglycerolized RED BLOOD CELLS None/XX/refg Open E Deglycerolized RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 E Deglycerolized RED BLOOD CELLS None/XX/refg Open Irradiated 7/11/2007 Page 7 of 14
8 E Apheresis RED BLOOD CELLS ACD-A>AS1/XX/refg Irradiated ResLeu:<5log6 E Apheresis RED BLOOD CELLS ACD-A>AS1/XX/refg Irradiated ResLeu:<5log6 1st E Apheresis RED BLOOD CELLS ACD-A>AS1/XX/refg Irradiated ResLeu:<5log6 2nd E Apheresis RED BLOOD CELLS ACD-A>AS1/XX/refg ResLeu:<5log6 E Apheresis RED BLOOD CELLS ACD-A>AS1/XX/refg ResLeu:<5log6 1st E Apheresis RED BLOOD CELLS ACD-A>AS1/XX/refg ResLeu:<5log6 2nd E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg 7/11/2007 E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg Irradiated E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg Irradiated ResLeu:<5log6 E Apheresis RED BLOOD CELLS ACD-A-AS3/XX/refg Irradiated ResLeu:<5log6 1st E Apheresis RED BLOOD CELLS ACD-A-AS3/XX/refg Irradiated ResLeu:<5log6 2nd E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg Irradiated 1st E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg Irradiated 2nd E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg ResLeu:<5log6 7/11/2007 E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg ResLeu:<5log6 1st E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg ResLeu:<5log6 2nd 7/11/2007 E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg 1st 2/22/2008 E Apheresis RED BLOOD CELLS ACD-A>AS3/XX/refg 2nd 7/11/2007 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 1st 7/28/2010 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 2nd 7/11/2007 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated 1st 7/28/2010 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated 2nd 7/28/2010 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 1st 3/17/2008 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 2nd 3/17/2008 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open 1st 7/28/2010 E Washed Apheresis RED BLOOD CELLS None/XX/refg Open 2nd 7/28/2010 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open 7/21/2008 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated 7/11/2007 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 7/11/2007 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 1st 7/11/2007 Page 8 of 14
9 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 2nd 7/11/2007 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open Irradiated 1st 7/11/2007 E Deglycerolized APHERESIS RED BLOOD CELLS None/XX/refg Open Irradiated 2nd 7/11/2007 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 1st E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 2nd E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open 1st 7/21/2008 E Deglycerolized Apheresis RED BLOOD CELLS None/XX/refg Open 2nd 7/21/2008 E RECOVERED PLASMA CPDA-1/XX/<=-18C For mnf:injectable Frozen <=120h Not for Txn E RED BLOOD CELLS CPDA-1/500mL/refg For mnf:noninjectable ResLeu:,<5log6 Not for Txn E RED BLOOD CELLS CPD>AS-1/500mL/refg For mnf:noninjectable ResLeu:,<5log6 Not for Txn E Apheresis PLATELETS ACD-A/XX/20-24C <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C 1st <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated 1st <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5log6 <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5log6 1st <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5log6 2nd <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5log6 <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5log6 1st <3 X log11 plts E Apheresis PLATELETS ACD-A/XX/20-24C Irradiated ResLeu:<5log6 2nd <3 X log11 plts E FRESH FROZEN PLASMA CPD/500mL/<=-18C 10/10/2016 E Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 1st 8/26/2016 E4689 A0 Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 1st 12/27/2011 E4689 B0 Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 1st 12/27/2011 E4689 C0 Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 1st 12/27/2011 E Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 2nd 8/26/2016 E Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 3rd 8/26/2016 E Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 4th 8/26/2016 E Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 1st 8/26/2016 Page 9 of 14
10 E Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 2nd 8/26/2016 E Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 3rd 8/26/2016 E Thawed Apheresis FRESH FROZEN PLASMA ACD-A/XX <=-18C 4th 8/26/2016 E RED BLOOD CELLS CPD/XX/refg LowVol:anticoag not adj E RED BLOOD CELLS CPD/XX/refg LowVol:anticoag adj E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open 1st 7/21/2008 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open 2nd 7/11/2007 E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C ResLeu:<5log6 E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C ResLeu:<5log6 1st E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C ResLeu:<5log6 2nd E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C ResLeu:<5log6 3rd E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C Irradiated ResLeu:<5log6 E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C Irradiated ResLeu:<5log6 1st E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C Irradiated ResLeu:<5log6 2nd E Apheresis PLATELETS - 7 d ACD-A/XX/20-24C Irradiated ResLeu:<5log6 3rd E Frozen RED BLOOD CELLS None/XX/<-65C Open E Frozen RED BLOOD CELLS None/XX/<-65C Open Irradiated 7/11/2007 E Frozen RED BLOOD CELLS None/XX/<-65C Open Irradiated ResLeu:<5log6 7/11/2007 E Frozen RED BLOOD CELLS None/XX/<-65C Open ResLeu:<5log6 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open 7/11/2007 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open Irradiated 7/11/2007 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open Irradiated 1st 7/11/2007 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open Irradiated 2nd 7/11/2007 E Frozen Apheresis RED BLOOD CELLS None/xx/<-65C Open Irradiated ResLeu:<5log6 7/11/2007 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open Irradiated ResLeu:<5log6 1st 7/11/2007 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open Irradiated ResLeu:<5log6 2nd 7/11/2007 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open ResLeu:<5log6 E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open ResLeu:<5log6 1st E Frozen Apheresis RED BLOOD CELLS None/XX/<-65C Open ResLeu:<5log6 2nd E Apheresis RED BLOOD CELLS CPDA-1/XX/refg Irradiated ResLeu:<5log6 Page 10 of 14
11 E Apheresis RED BLOOD CELLS CPDA-1/XX/refg Irradiated ResLeu:<5log6 1st E POOLED PLATELETS CPD/XX/20-24C Open ResLeu:<5log6 E POOLED PLATELETS CPDA-1/XX/20-24C Open ResLeu:<5log6 E POOLED PLATELETS CPD/XX/20-24C Open E POOLED PLATELETS CPDA-1/XX/20-24C Open E RED BLOOD CELLS CPDA-1/XX/refg ResLeu:<5log6 LowVol:anticoag adj 5/21/2010 E Washed RED BLOOD CELLS None/XX/refg Open 7/11/2007 E CRYOPRECIPITATE None/XX/<=-18C 12/20/2011 E Washed RED BLOOD CELLS None/XX/refg Open Irradiated 7/21/2008 E Washed RED BLOOD CELLS None/XX/refg Open ResLeu:<5log6 E Washed RED BLOOD CELLS None/XX/refg Open Irradiated ResLeu:<5log6 E Frozen Rejuvenated RED BLOOD CELLS None/XX/<-65C Open E Deglycerolized Rejuvenated RED BLOOD CELLS None/XX/refg Open 7/11/2007 E PLATELETS CPD/500mL/20-24C For mnf:non-injectable Not for Txn E PLATELETS CPDA-1/500mL/20-24C For mnf:non-injectable Not for Txn E POOLED PLATELETS CPD/XX/20-24C Open Irradiated E POOLED PLATELETS CPDA-1/XX/20-24C Open Irradiated E POOLED PLATELETS CPD/XX/20-24C Open Irradiated ResLeu:<5log6 E POOLED PLATELETS CPDA-1/XX/20-24C Open Irradiated ResLeu:<5log6 E RED BLOOD CELLS CPDA-1/XX/refg Irradiated LowVol:anticoag not adj 7/11/2007 E Rejuvenated RED BLOOD CELLS None/XX/refg Open E RECOVERED PLASMA CPD/XX/<=-20C For mnf:injectable Frozen <=120h E PLATELETS CPD/500mL/20-24C Open ResLeu:<8.3log5 Plasma reduced 11/12/2007 E PLATELETS CPD/500mL/20-24C Open Irradiated ResLeu:<8.3log5 Plasma reduced 11/12/2007 E PLATELETS CPD/500mL/20-24C Open Plasma reduced 11/12/2007 E PLATELETS CPD/500mL/20-24C Open Irradiated Plasma reduced 11/12/2007 E Pooled PLATELETS CPD/XX/20-24C Open Plasma reduced 11/12/2007 E Pooled PLATELETS CPD/XX/20-24C Open Irradiated Plasma reduced 11/12/2007 E Pooled PLATELETS CPD/XX/20-24C Open ResLeu:<5log6 Plasma reduced 11/12/2007 E Pooled PLATELETS CPD/XX/20-24C Open Irradiated ResLeu:<5log6 Plasma reduced 11/12/2007 Page 11 of 14
12 E PLATELETS CPD/500mL/<37C For mnf:noninjectable Not for Txn E RED BLOOD CELLS CPDA-1 /XX/refg Irradiated ResLeu:<5log6 LowVol:anticoag adj 5/21/2010 E Apheresis PLATELETS ACDA-A/XX/<37C For mnf:noninjectable 1st Not for Txn E Apheresis PLATELETS ACDA-A/XX/<37C For mnf:noninjectable 2nd Not for Txn E Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C Open 1/16/2009 E5730 A0 Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C Open 1/16/2009 E5730 B0 Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C Open 1/16/2009 E5730 C0 Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C Open 1/16/2009 E5730 D0 Apheresis FRESH FROZEN PLASMA NaCitrate/XX/<=-18C Open 1/16/2009 E Pooled PLATELETS CPD/XX/20-24C IrradiatedResLeu:<5log6 Bacterial test 1/16/2009 E Pooled PLATELETS CPD/XX/20-24C ResLeu:<5log6 Bacterial test 1/16/2009 E Washed Apheresis PLATELETS None/XX/20-24C Open Irradiated ResLeu:<5log6 <3log11 plts 6/1/2011 E Washed Apheresis PLATELETS None/XX/20-24C Open ResLeu:<5log6 <3log11 plts 6/1/2011 E Apheresis PLASMA ACD-A/XX/<=-18C Frozen <=24h 1st 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C Frozen <=24h 2nd 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C Frozen <=24h 3rd 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C Frozen <=24h 4th 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C RT<=24h frozen<=24h 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C RT<=24h frozen<=24h 1st 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C RT<=24h frozen<=24h 2nd 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 1st Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 2nd Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 3rd Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 <3E11 plts Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Pediatric dose Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 1st Pediatric dose Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 2nd Pediatric dose Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 3rd Pediatric dose Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 Psoralen-treated 10/10/2016 Page 12 of 14
13 E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 1st Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 2nd Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 3rd Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 <3E11 plts Psoralen-treated 10/10/2016 E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 Pediatric dose Psoralen-treated 10/10/2016 E E E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 1st Pediatric dose Psoralentreated 10/10/2016 Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 2nd Pediatric dose Psoralentreated 10/10/2016 Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 3rd Pediatric dose Psoralentreated 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C Psoralen-treated 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C <200 ml Psoralen-treated 10/10/2016 E Apheresis PLASMA ACD-A/XX/<=-18C >=200mL<400mL Psoralen-treated 10/10/2016 E POOLED PLASMA CPD/XX/<=-18C Frozen <=24h 2 units Psoralen-treated 10/10/2016 E POOLED PLASMA CPD/XX/<=-18C Frozen <=24h 3 units Psoralen-treated 10/10/2016 E POOLED PLASMA CPD/XX/<=-18C Frozen <=24h Psoralen-treated 10/10/2016 E POOLED PLASMA CPDA-1/XX/<=-18C 2 units Psoralen-treated 10/10/2016 E POOLED PLASMA CPDA-1/XX/<=-18C 3 units Psoralen-treated 10/10/2016 E POOLED PLASMA CPDA-1/XX/<=-18C Psoralen-treated 10/10/2016 E POOLED PLASMA CP2D/XX/<=-18C Frozen <=24h 2 units Psoralen-treated 10/10/2016 E POOLED PLASMA CP2D/XX/<=-18C Frozen <=24h 3 units Psoralen-treated 10/10/2016 E POOLED PLASMA CP2D/XX/<=-18C Frozen <=24h Psoralen-treated 10/10/2016 E Thawed Apheresis PLASMA ACD-A/XX/refg Psoralen-treated 11/14/2016 E Thawed Apheresis PLASMA ACD-A/XX/refg <200 ml Psoralen-treated 11/14/2016 E Thawed Apheresis PLASMA ACD-A/XX/refg >=200mL<400mL Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CPD/XX/refg Frozen <=24h 2 units Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CPD/XX/refg Frozen <=24h 3 units Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CPD/XX/refg Frozen <=24h Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CPDA-1/XX/refg 2 units Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CPDA-1/XX/refg 3 units Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CPDA-1/XX/refg Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CP2D/XX/refg Frozen <=24h 2 units Psoralen-treated 11/14/2016 Page 13 of 14
14 E Thawed POOLED PLASMA CP2D/XX/refg Frozen <=24h 3 units Psoralen-treated 11/14/2016 E Thawed POOLED PLASMA CP2D/XX/refg Frozen <=24h Psoralen-treated 11/14/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Plasma reduced Psoralen-treated 11/30/2016 E E E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Plasma reduced 1st Psoralentreated Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Plasma reduced 2nd Psoralentreated Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Plasma reduced 3rd Psoralentreated 11/30/ /30/ /30/2016 E Apheresis PLATELETS ACD-A/XX/20-24C ResLeu:<5E6 Plasma reduced <3E11 plts Psoralen-treated 11/30/2016 E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 Plasma reduced Psoralen-treated 11/14/2016 E E Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 Plasma reduced 1st Psoralen-treated Apheresis PLATELETS ACD-A>PAS-C/XX/20-24C ResLeu:<5E6 Plasma reduced 2nd Psoralen-treated Removed E3573 Cryoprecipitate; E5165 is preferred Removed E3678 Granulocytes Pheresis (not open) Removed E5994 Pooled Platelets Irradiated; E5803 is preferred Removed E5995 Pooled Platelets; E6001 is preferred. 11/14/ /14/2016 Page 14 of 14
Memorial Blood Centers A Division of Innovative Blood Resources
Memorial Blood Centers Hospital Resource Guide Memorial Blood Centers A Division of Innovative Blood Resources We create trusted and innovative solutions to help our customers achieve their goals Table
Blood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories
Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories Blood Products From the Donor to You Objectives Deliver a brief virtual tour of a blood center. Describe the number of donors needed to meet the
Implementing 7 Day Platelet Dating with the Platelet PGD Test
Implementing 7 Day Platelet Dating with the Platelet PGD Test Paul D. Mintz, M.D., Chief Medical Officer, Verax Biomedical Incorporated The Verax Biomedical Platelet Pan Genera Detection (PGD ) Test is
Blood Supply and Wastage
Blood Supply and Wastage Inga Willett Lab Matters, Oake Manor, 21 st June 2017 Blood supply UK supplied by 4 blood services: SNBTS NIBTS NHSBT WBS http://commons.wikimedia.org/wiki/file:uk_map_home_nations.png
The ABC s of Blood Components. Terry Downs, MT(ASCP)SBB Administrative Manager University of Michigan Hospitals Blood Bank and Transfusion Service
The ABC s of Blood Components Terry Downs, MT(ASCP)SBB Administrative Manager University of Michigan Hospitals Blood Bank and Transfusion Service Objectives Describe three additives used in blood components.
Transfusion Medicine III
Transfusion Medicine III Blood Products from Collection to Use D. Joe Chaffin, MD Loma Linda University 3/5/2019 FFP WB RBC Anticoagulant/Preservatives Why we need 21 Day Shelf Life Prevent clotting Keep
The primary goal of collection
7 Blood and Components 7 The primary goal of collection centers is to ensure that processes involved in the collection, preparation, storage, and shipment of blood and components result in a blood or blood
Presentation Created by; Shana Chiborak RN CNCC (C) Nurse Coordinator Blood Management Service May 2016
Presentation Created by; Shana Chiborak RN CNCC (C) Nurse Coordinator Blood Management Service May 2016 What is Cryoprecipitate? Cryoprecipitate contains factor VIII (8), fibrinogen, and von Willebrand
What is an Apheresis Donation?
What are Platelets? Platelets are colorless, irregularly shaped bodies found in blood. The primary role of platelets is to prevent bleeding in injured blood vessel walls by forming an aggregate at the
UKGS TRANSFUSION SERVICE PRODUCTS AND AVAILABILITY
Lexington, KY Page 1 of 13 Affected Sites: Enterprise Chandler X Good Samaritan I. PRINCIPLE: The UK Good Samaritan Hospital is dedicated to serve the patients with safe, high quality blood products and
GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
Guidelines for Use of Canine Blood Components
Guidelines for Use of Canine Blood Components Cryoprecipitate This product is prepared by a controlled thaw of fresh frozen plasma, resulting in a concentration of Factor VIII, Factor XIII, vwf and some
The New Zealand Experience
Platelet Collections using TRIMA. The New Zealand Experience Dr Anup Chand 20th November 2016 Disclaimer I have no financial interest in TERUMO BCT or any other company Content Introduction Donor PAS
CELLULAR THERAPY QUIZ. Correct answers and rationale
CELLULAR THERAPY QUIZ Correct answers and rationale In January 2018, registered cellular therapy (CT) facilities were asked to participate in the quiz to determine the educational needs of the users regarding
For the use of Labile Blood Products
For the use of Labile Blood Products CIRCULAR of information FEBRUARY 2014 Edition WARNING: The risk of transmitting known and unknown infectious disease agents is present in the transfusion of labile
2. Screening Process POLICY FOR THE DISTRIBUTION OF IGA-DEFICIENT PLASMA. 1. Scope
POLICY FOR THE DISTRIBUTION OF IGA-DEFICIENT PLASMA 1. Scope The ARDP is responsible for identifying the locat ion(s) of IgA-deficient plasma and request shipment of such products to authorized requesting
Transfusion Medicine Best Practices: Indications for Blood Components
Transfusion Medicine Best Practices: 1.0 Policy Statements 1.1 Regional Health Authorities (RHAs) shall develop policies, processes and procedures for ordering, distribution, storage, transfusion and administration
Description. Specifications and Ordering Information Proximitor Sensor / interface module/ VDC Housings
Specifications and Ordering Information Proximitor Sensor / interface module/ VDC Housings R Description Although Proximitor and interface are rugged by design, these units and their electrical connections
CIRCULAR. of information. For the use of Labile Blood Products. Edition
For the use of Labile Blood Products CIRCULAR of information july 2009 Edition WARNING: The risk of transmitting known and unknown infectious disease agents is present in the transfusion of labile blood
CIRCULAR OF INFORMATION
CIRCULAR OF INFORMATION FOR THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS This Circular was prepared jointly by AABB, the American Red Cross, America s Blood Centers, and the Armed Services Blood Program.
Blood Product Modifications: Leukofiltration, Irradiation and Washing
1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs
Crossmatching and Issuing Blood Components; Indications and Effects.
Crossmatching and Issuing Blood Components; Indications and Effects. Alison Muir Blood Transfusion, Blood Sciences, Newcastle Trust Topics Covered Taking the blood sample ABO Group Antibody Screening Compatibility
New Advances in Transfusion EM I LY CO BERLY, M D
New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for
ADULT TRANSFUSION GUIDELINES ORDERED COMPONENT
ADULT TRANSFUSIN GUIDELINES RDERED Packed red cells (RBCs) RBCs, WBCs, platelets & plasma (minimal) Increase red cell mass and oxygen carrying capacity; generally indicated when Hgb is 7 gm or Hct 21 unless
PROPOSED TECHNICAL REQUIREMENTS BLOOD AND BLOOD COMPONENTS. File 1 DRAFT FOR CONSULTATION PURPOSES ONLY
PROPOSED TECHNICAL REQUIREMENTS BLOOD AND BLOOD COMPONENTS File 1 DRAFT FOR CONSULTATION PURPOSES ONLY ANNEX I INFORMATION REQUIREMENTS A. INFORMATION TO BE PROVIDED TO DONORS 1. Accurate but generally
Special Requirements Lab Matters. 18 th May Katy Cowan PBM Practitioner NHSBT
Special Requirements Lab Matters. 18 th May 2016 Katy Cowan PBM Practitioner NHSBT Special requirements Frozen components and platelets HEV negative Irradiated CMV negative Frozen components and platelets
Blood/Blood Component Utilization and Administration Annual Compliance Education
Blood/Blood Component Utilization and Administration Annual Compliance Education This course contains annual compliance education necessary to meet compliance and regulatory requirements. Instructions:
Transfusion Pitfalls. Objectives. Packed Red Blood Cells. TRICC trial (subgroups): Is transfusion always good? Components
Objectives Transfusion Pitfalls Gregory W. Hendey, MD, FACEP Professor and Chief UCSF Fresno, Emergency Medicine To list risks and benefits of various blood products To discuss controversy over liberal
Consent Laboratory Transfuse RBC
Peds Blood Product Infusion Order Set (386) [386] Blood product review will be performed unless exclusion criteria met. MD: Please note if transfusion giv en outside of parameter, please justify use in
Abstract for Blood Bag Production. This abstract refers to blood bag production considering general and process information
Abstract for Blood Bag Production This abstract refers to blood bag production considering general and process information 1 BLOOD BAGS Blood donation and processing with these system is supplemented by
Blood Component Information. CIRCULAR OF INFORMATION An extension of blood component labels
Blood Component Information CIRCULAR OF INFORMATION An extension of blood component labels 2009 Copyright Australian Red Cross Blood Service 2009 Last updated April 2009 Apart from any fair dealing for
Special Requirements Lab Matters. 21 st June Barrie Ferguson
Special Requirements Lab Matters. 21 st June 2017 Barrie Ferguson Special requirements Patients requiring Methylene Blue or Solvent Detergent treated Fresh Frozen Plasma Patients requiring apheresis platelets
Guide to the preparation, use and quality assurance of blood components
Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.
COMPONENT SECTION MANUAL THE PROCEDURE FOR THE PREPARATION OF WHOLE BLOOD FOR NEONATAL EXCHANGE TRANSFUSION
SOP from a Massachusetts BLOOD BANK DONOR/TRANSFUSION SERVICE COMPONENT SECTION MANUAL THE PROCEDURE FOR THE PREPARATION OF WHOLE BLOOD FOR I. PURPOSE: To describe the steps necessary to prepare reconstituted
2/2/2011. Blood Components and Transfusions. Why Blood Transfusion?
Blood Components and Transfusions Describe blood components Identify nursing responsibilities r/t blood transfusion Discuss factors r/t blood transfusion including blood typing, Rh factor, and cross matching
Components of Blood. N26 Blood Administration 4/24/2012. Cabrillo College ADN/C. Madsen RN, MSN 1. Formed elements Cells. Plasma. What can we give?
Components of Blood Formed elements Cells Erythrocytes (RBCs) Leukocytes (WBCs) Thrombocytes (platelets) Plasma 90% water 10% solutes Proteins, clotting factors 1 What can we give? Whole blood Packed RBC
TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:
I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related
Duration: 12 months May to April
SPECIALIST CERTIFICATE IN TRANSFUSION SCIENCE PRACTICE PROGRAMME OF STUDY OVERVIEW Example only Duration: 12 months May to April This document serves as a general programme overview only. To ensure you
Private Patients Pricelist
Private Patients Pricelist Valid 1 January 2017-31 December 2017 INF-ACC-006 1043973 Rev 0 (01/06/17) Reg No. 2000/026390/08 Private Diagnostic Services Nappi 10580 Packaging R75.14 R85.66 15016 Low Ionic
Edwin A. Burgstaler MT, HP (ASCP) Jeffrey L. Winters MD. ASFA 2017 Annual Meeting May 5, MFMER slide-1
Comparison of Hematopoietic Progenitor Cell (HPC) Collection Using the Spectra Optia Continuous Mononuculear Cell (CMNC) Collections with a 26:1 Anticoagulant Ratio Versus an Anticoagulant ing Technique
Armed Services Blood Program
Armed Services Blood Program Defense Health Board Concerns Regarding the Collection and Transfusion of Non-FDA Compliant Blood Products in Theater Information Brief Defense Health Board 17 August 2009
FOR THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS
CIRCULAR OF INFORMATION FOR THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS This Circular was prepared jointly by AABB, the American Red Cross, America s Blood Centers, and the Armed Services Blood Program.
Document for Obstetric Patients Who Refuse Consent for Blood and Blood Product Administration, Including Jehovah s Witnesses
Document for Obstetric Patients Who Refuse Consent for Blood and Blood Product Administration, Including Jehovah s Witnesses Patient addressograph Label This form must only be used for the refusal of blood
Experiences with frozen blood products in the Afghan theater (Aug 2006 Aug 2008)
Experiences with frozen blood products in the Afghan theater (Aug 2006 Aug 2008) CCM Lelkens, SBB(ASCP) Cdr (MC) (Royal Netherlands Navy) CO NLD Military Blood Bank 1 Outline Introduction ISAF / OEF facts
Pediatric massive transfusion protocols
University of New Mexico UNM Digital Repository Emergency Medicine Research and Scholarship Emergency Medicine 2014 Pediatric massive transfusion protocols Ramsey Tate Follow this and additional works
Acute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11
REACTIONS IN PATIENTS: Serious adverse reactions including EU definition ANNUAL SHOT REPORT 2015 Acute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11 Authors: Janet Birchall,
Olle Berséus MD, PhD Ass.professor Department for Transfusion Medicine Örebro University Hospital Sweden
Olle Berséus MD, PhD, Ass.professor Department for Transfusion Medicine Örebro University Hospital Sweden Medical advisor in transfusion medicine to the Swedish Armed Forces. Does WHOLE BLOOD need to be
Specific Requirements
Specific Requirements AIMS Specific requirements your patients have for transfusion and how this is managed Classify which patients require: Irradiated components CMV negative components Washed components
Transfusion 2004: Current Practice Standards. Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service
Transfusion 2004: Current Practice Standards Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service Massive Transfusion Protocol (MTP) When should it be activated? Massive bleeding i.e. loss of one blood
ACCEPTABLE UNIVERSAL BLOOD PRODUCTS FOR RESUSCITATION?
ACCEPTABLE UNIVERSAL BLOOD PRODUCTS FOR RESUSCITATION? Paul M. Ness, M.D. Professor Pathology, Medicine, and Oncology The Johns Hopkins Medical Ins tu ons Bal more, Maryland, USA BLOOD BANK BUREAUCRATS
By the end of this talk you should be able to:
Blood Components Learning Objectives By the end of this talk you should be able to: List the components made from whole blood Describe how blood products are produced and stored Understand the Indications
Bassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: MTP 2016 Revision: 2.00 Created By: Admin, The Last
Bassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: MTP 2016 Revision: 2.00 Created By: Admin, The Last Approved Time: 7/22/2016 12:44:54 PM Massive Transfusion
Learning Objectives. Blood Component Therapy. Blood Component Therapy. Apheresis Technology. Red Cells
Learning Objectives Blood Component Therapy Jeffrey Jhang, MD Assistant Professor of Clinical Pathology College of Physicians and Surgeons New York, NY 1. Know how components are prepared by whole blood
Blood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
Norovirus Surrogate Test Exposure to SixLog s ihp TM (ionized Hydrogen Peroxide) Decontamination Technology. Executive Summary:
Norovirus Surrogate Test Exposure to SixLog s ihp TM (ionized Hydrogen Peroxide) Decontamination Technology Executive Summary: The ihp TM decontamination technology was used to kill a human norovirus surrogate
Melanoma Bridge Meeting
Melanoma Bridge Meeting Improving Adoptive Immune Therapy with Genetically Engineered T cells David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH 3 December 2015 Adoptive T Cell Therapy: Dose
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
Hot topics in Paediatric Transfusion and the Emergency Provision from the Blood Transfusion Laboratory. Margaret Slade
Hot topics in Paediatric Transfusion and the Emergency Provision from the Blood Transfusion Laboratory Margaret Slade What is the difference between Transfusion Practice in Paediatrics and Adults? Age
PRIVATE PRICELIST (Amendment) with effect from 01 April 2018
PRIVATE PRICELIST (Amendment) with effect from 01 April 2018 Whole Blood Products 702074001 78001 WB Whole Blood 513ml ± 45ml R 1 711.40 R 1 968.11 702079001 78677 WB96 Whole Blood -
Paired Comparison of Therapeutic Plasma Exchange using Fenwal Amicus vs. TerumoBCT Spectra Optia
Paired Comparison of Therapeutic Plasma Exchange using Fenwal Amicus vs. TerumoBCT Spectra Optia Edwin A. Burgstaler MT, HP (ASCP) Sandra C. Bryant M.S. Jeffrey L. Winters M.D. ASFA Annual Meeting May
Aerobic Wound Culture and Stain
Aerobic Wound Culture and Stain Order Name: C WOUN RTS Test Number: 6000153 Revision Date: 03/27/2014 Aerobic Wound Culture and Stain Culture Preferred 1 ml Tissue Sterile Screwtop Container Room Temperature
Plasma therapy : indications &
Plasma therapy : indications & recommendations in France F. HESHMATI 3rd International congress of Transfusion Medicine Iran, Tehran Available types of therapeutic plasma In France, EU & USA Cll Collection
It s a bird, It s a plane, No It s a. Presented by Julie Kirkegaard & Miche Swofford
It s a bird, It s a plane, No It s a Presented by Julie Kirkegaard & Miche Swofford 55 year old woman admitted 11/23/2015 for colon cancer that metastasized to her liver History of 3 pregnancies Surgery
INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono
INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE Yuyun SM Soedarmono 1 BACKGROUND Indonesia has more than 240 million population and approximately 25,000 hemophilia A patients Hemophilia A patients
TRANSFUSION MEDICINE UPDATE & REVIEW TOO MUCH OF A GOOD THING? YELENA KIER, DO
TRANSFUSION MEDICINE UPDATE & REVIEW TOO MUCH OF A GOOD THING? YELENA KIER, DO DISCLOSURES No Disclosures/Conflicts of interest OVERVIEW Brief overview of history of transfusion medicine Review of blood
State Patients Pricelist. 1 April March 2019
State Patients Pricelist 1 April 2018 31 March 2019 State Diagnostic pricing 2018 10580 Packaging R 75,50 R 86,83 15016 Low Ionic Reagent 15ml R 169,33 R 194,83 78004 Whole Blood Reagent R 702,11 R 807,43
Private Patients Pricelist. 1 April December 2018
Private Patients Pricelist 1 April 2018 31 December 2018 Private Diagnostic pricing 2018 10580 Packaging R 78,52 R 90,31 15016 Low Ionic Reagent 15ml R 151,47 R 174,19 78004 Whole Blood Reagent R 867,82
Research Article. Trauma and Emergency Care ISSN: Introduction. Valeri CR*, Giorgio GR and CA Valeri
Trauma and Emergency Care Research Article ISSN: 2398-3345 The therapeutic effectiveness and safety of universal donor group O frozen RBC, group O frozen platelets, and group AB frozen plasma to treat
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress TRANSFUSIONS CONTAINING RED BLOOD CELLS Ann E. Hohenhaus, DVM Diplomate, ACVIM (Oncology and Internal Medicine)
Source of platelet concentrates FACHBEREICH MEDIZIN
FACHBEREICH MEDIZIN Efficacy and safety of platelet concentrates from platelet apheresis donations or whole blood donations Gregor Bein Institute for Clinical Immunology and Transfusion Medicine Justus-Liebig-University
Fresh Frozen Plasma (FFP) and Cryoprecipitate Patient information
Fresh Frozen Plasma (FFP) and Cryoprecipitate Patient information What are Fresh Frozen Plasma (FFP) and Cryoprecipitate? FFP and Cryoprecipitate (often just called cryo ) are both blood components made
Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL
Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL CASE HISTORY 4 yrs old previously well boy Born to 2 nd degree consanguinity Fever x 5 days
CMC Medical Staff Transfusion Guidelines. Table of Contents edition INTRODUCTION:
CMC Medical Staff Transfusion Guidelines 2014 edition INTRODUCTION: The CMC Blood Component and Transfusion Guidelines have been approved by the multidisciplinary Transfusion Committee. These are based
Behzad Poopak, DCLS PhD
Behzad Poopak, DCLS PhD Test Report Name Age Critical Low HEMATOLOGY Activated Partial Thromboplastin Time, Plasma Critical High - 150 sec Units Fibrinogen 60 - mg/dl INR (International Normalizing
Transfusion Medicine Kris0ne Kra1s, M.D.
Transfusion Medicine Kris0ne Kra1s, M.D. Transfusion Medicine Outline Blood groups Introduc0on ABO system Rh system Other systems Blood transfusion Blood products Indica0ons Tes0ng Dangers Transfusion
The testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
Proceedings of the 35th World Small Animal Veterinary Congress WSAVA 2010
www.ivis.org Proceedings of the 35th World Small Animal Veterinary Congress WSAVA 2010 Geneva, Switzerland - 2010 Next WSAVA Congress : Reprinted in IVIS with the permission of WSAVA D40 TRANSFUSION MEDICINE
New recommendations for immunocompromised patients
New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption
TRANSFUSION SAFETY 101 ARE YOU SMARTER THAN A BLOOD BANKER?
TRANSFUSION SAFETY 101 ARE YOU SMARTER THAN A BLOOD BANKER? 1. Fatal blood transfusion reactions are most likely the result of: a. Circulatory overload b. ABO incompatible blood due to patient identification
TITLE CLIN_092 ADMINISTRATION OF BLOOD AND BLOOD COMPONENTS
Policies and procedures are guidelines and are not a substitute for the exercise of individual judgment. If you are reading a printed copy of this policy, make sure it is the most current by checking the
Guidelines for Gamma Irradiation of Blood Components
AUSTRALIAN & NEW ZEALAND SOCIETY OF BLOOD TRANSFUSION INC. AUSTRALIAN RED CROSS BLOOD SERVICE NEW ZEALAND BLOOD SERVICE Guidelines for Gamma Irradiation of Blood Components Revised 2003 AN ZS B T Australian
Blood Bank Instructions
Blood Bank Instructions Blood Bank Transfusion Services Available at MidMichigan Laboratories-Clare, MidMichigan Laboratories-Gladwin, MidMichigan Laboratories-Gratiot, and MidMichigan Laboratories-Midland
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
Transfusion Therapy & Safety. Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015
Transfusion Therapy & Safety Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015 Topics Blood Components Special Processing/Attributes Irradiation Leukoreduction
1) unexplained microangiopathic hemolytic anemia (Coombs negative anemia),
Ravi Sarode, MD Consensus Process The TTP-CC subcommittee developed 7 key questions Sent to the 7 speakers for electronic voting in Yes or No format Will be published in JCA soon Q.1 Untreated TTP carries
Blood bags Short description
Blood bags Short description Exclusive Partner : www.bmct.pl info@bmct.pl COMPANY DESCRIPTION RAVIMED Ltd Liability Company, a producer of medical equipment, was created in 1991. It provides: single use
Transfusion Management of IgA deficiency. Emily Coberly, MD Medical Director, Transfusion Services University of Missouri Columbia
Transfusion Management of IgA deficiency Emily Coberly, MD Medical Director, Transfusion Services University of Missouri Columbia Our patient 63 year-old female with a duodenal stricture who was admitted
Pathogenreduktion mittels UVC-Licht: Entwicklung des THERAFLEX UV-Plättchen-Systems
Pathogenreduktion mittels UVC-Licht: Entwicklung des THERAFLEX UV-Plättchen-Systems Pathogen reduction by UVC light: Development of the THERAFLEX UV-Platelets system Fribourg 2011 Prof. Dr. Axel Seltsam,
Tables e1a-d. Diagnostic and drug codes for the identification of the multiple sclerosis population, DMT exposures, and study outcomes
Appendix Tables e1a-d. Diagnostic and drug codes for the identification of the multiple sclerosis population, DMT exposures, and study outcomes Table e-1a Multiple sclerosis and demyelinating disease related
What can we learn from cryopreserved blood cells?
What can we learn from cryopreserved blood cells? Andreas Sputtek Universitätsklinikum Hamburg-Eppendorf Inst. f. Transfusionsmedizin Hamburg, Germany http://www.sputtek.de Plenary Lecture (Definition)
White Cell Depletion for Leukocytosis
White Cell Depletion for Leukocytosis Objectives Discuss the indication for leukoreduction Identify IV access needs for patients receiving leukapheresis Outline ways to maintain fluid and electrolyte balance
Blood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?
What is blood transfusion? A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. A blood transfusion usually takes two to
BLOOD COMPONENT SUPPORT OF RhD NEGATIVE INDIVIDUALS
REASON FOR ISSUE: Review of section 4 along with changes in requirement to inform TMS in respect of authorisation process (in Appendix A) DCR16969. 1. INTRODUCTION of RhD positive blood components to an
BIOCHEMISTRY OF BLOOD
BCH 471 BIOCHEMISTRY OF BLOOD Amal Alamri Experiment 1 Separation of Plasma and Serum from Whole Blood Whole Blood It is living tissue that circulates through the heart, arteries, veins, and capillaries
The Possible Advantages of Cryoprecipitate Prepared From Fresh Frozen Plasma From Blood Stored for 24 Hours
The Possible Advantages of Cryoprecipitate Prepared From Fresh Frozen Plasma From Blood Stored for 24 Hours Joseph Philip, MD, 1* Samantha Kumarage, MBBS, 1 Tathagata Chatterjee, DM, 1 Sudeep Kumar, MBBS,
Clinical Trial of Young Red Blood Cells Prepared by Apheresis
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 16, No. 6 Copyright 1986, Institute for Clinical Science, Inc. Clinical Trial of Young Red Blood Cells Prepared by Apheresis PATRICIA PISCIOTTO, M.D.,* THOMAS
European Society of Anaesthesiologists CLINICAL CONSEQUENCES OF LEUKOCYTE REDUCTION
European Society of Anaesthesiologists CLINICAL CONSEQUENCES OF LEUKOCYTE REDUCTION 6RC2 HANS GOMBOTZ AND A. DEHKHARGHANY Department of Anesthesiology and Intensive Care, General Hospital Linz Linz, Austria
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
Update on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets
Update on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets Axel Seltsam, MD, MHBA German Red Cross Blood Service NSTOB, Springe Fribourg 2011 THERAFLEX UV-Platelets Efficient